Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 159

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 159
---
 the Hebrew University of Jerusalem. The nineteen patent families include thirty granted patents and fifty three pending applications:

| ● | Binge Behavior Regulators: 21 patents, 4 pending applications. The “Binge Behavior Regulators” family has a 20-year term that ends December, 9, 2035. |

95

| ● | Psychoactive compounds, methods of their preparation and uses thereof in the treatment of mental disorders: 1 pending application |

| ● | Psychedelic compounds, methods of their preparation and uses thereof: 1 pending application |

The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. The Alcoholic Beverage Substitute patent family discloses a large genus of compounds suitable for use in alcoholic beverage substitutes comprising a derivative of 2-aminoindan having the characteristics of being intoxicating in a way like alcohol, being physiologically benign (non-harmful), and being devoid of interactions with other drugs. A disclosed species of the genus is MEAI. 96 The Binge Behavior Regulators patent family discloses compositions comprising a derivative of 2-aminoindan, as described herein, useful as binge regulators or binge mitigation agents that impart a feeling of satisfaction, satiety or contentedness and thereby regulate (e.g., discourage) binge behavior such as binge drinking. The Benzofurans as Fail Safes for MDMA Therapy patent family discloses a method for treating subjects who are resistant to MDMA-assisted psychotherapy, or those for whom MDMA has become ineffective, undesirable, or inappropriate. The 2-FDCK for Treatment of Depression, Including Treatment-Resistant Depression patent family is directed to methods of administering 2-fluorodeschloroketamine to treat depression, including depression in patients who have developed resistance to previously used treatment therapies, such as ketamine. Compositions comprising MEAI and n-acylethanolamines and uses thereof patent family is part of our cooperation agreement with SciSparc. The invention disclosed therein is directed to the compositions and methods for potentiating therapeutic effects and/or reducing side-effects of MEAI. The present invention provides pharmaceutical compositions comprising MEAI and N-acylethanolamines, for example, Palmitoylethanolamide, or PEA, and methods for their use in a variety of indications amenable to treatment with MEAI. MEAI for the Treatment of Cocaine Addiction patent family was filed jointly with BIRAD on May